Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1
Krina Patel(The University of Texas MD Anderson Cancer Center), Matthew J. Frigault(Harvard University), Tim Welliver, Carolyn Jackson, Cindy Varga, Larry D. Anderson(Dana-Farber Cancer Institute), Natalie S. Callander(University of Wisconsin–Madison), Enrique Granados(Spanish Society of Hematology and Hemotherapy), Carolina Schinke(University of Arkansas for Medical Sciences), Abhinav Deol(Wayne State University), Noa Biran(Hackensack University Medical Center), Douglas W. Sborov(University of Utah), Mehmet H. Kocoglu(University of Maryland, Baltimore), Gurbakhash Kaur(The University of Texas Southwestern Medical Center), Krishna Rana(Gilead Sciences (Australia)), Abraham S. Kanate(HonorHealth), Adam S. Sperling(Dana-Farber Cancer Institute), Richard T. Maziarz(Oregon Health & Science University), Andrzej Jakubowiak(University of Chicago), Ciara Louise Freeman(Moffitt Cancer Center), Christopher R. Heery(National Cancer Institute), Binod Dhakal(Medical College of Wisconsin), Melhem Solh(Johns Hopkins Hospital), Ana Kostić(Agriculture and Agri-Food Canada), Kamalika Banerjee(XCell Science (United States))
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k